检索结果-南通市图书馆

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

热采注入井压降试井

国外油气科技 1995年第2期 9-14页

作者： wals.,JW 黄鹏

根据注入井压力不稳定试井来找出确定波及体积的矿场实例已进行过研究。在早期研究中，求解双区油藏压力不稳定模型用的是解析法，该法原则上既可确定渗透率－厚度乘积ｋｈ，又可确定两个区的波及体积。依照该模型，一条典型压降曲线由... 详细信息

根据注入井压力不稳定试井来找出确定波及体积的矿场实例已进行过研究。在早期研究中，求解双区油藏压力不稳定模型用的是解析法，该法原则上既可确定渗透率－厚度乘积ｋｈ，又可确定两个区的波及体积。依照该模型，一条典型压降曲线由三段组成：开始是第一段半对数直线、之后是过渡段、最后是第二段半对数直线。过渡段包含一条拟稳态苗卡尔直线段，其斜率与波及体积有关，为验证该直线段的存在，考察了几组矿场试井数据。

关键词：热力驱油注入井试井压力降

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

采用超声波测流技术的水电站现场效率试验

水电厂自动化 1991年第3期12卷 51-55页

作者： wals.,JT 王跃

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

水力式封隔器：生产应用

采油工艺情报 1989年第3期 94-108页

作者： wals.,MD 张怀文

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

抗痫灵对大鼠点燃模型的抗痫性

北京医科大学学报 1994年第5期26卷 355-356页

作者：王丽 wals.,PD 北京医科大学第一医院儿科研究室

评价国产新药抗痫灵（ＡＥＳ）对大鼠两种点燃模型的抗痫性。戊四唑（ＰＴＺ）点燃大鼠随机分４组（ｎ＝５），分别口服ＡＥＳｌ５０、３００、５００ｍｇ／ｋｇ／日或溶剂：杏仁核（ＡＭ）完全点燃大鼠随机分２组（ｎ＝５），分别口服... 详细信息

评价国产新药抗痫灵（ＡＥＳ）对大鼠两种点燃模型的抗痫性。戊四唑（ＰＴＺ）点燃大鼠随机分４组（ｎ＝５），分别口服ＡＥＳｌ５０、３００、５００ｍｇ／ｋｇ／日或溶剂：杏仁核（ＡＭ）完全点燃大鼠随机分２组（ｎ＝５），分别口服ＡＥＳ５００ｍｇ／ｋｇ／日或溶剂。共维持４周。分别用ＰＴＺ或电流刺激测试其抗痫效果，每周一次。结果：ＡＥＳ对ＰＴＺ点燃有效，且呈剂量依赖性；ＡＥＳ对ＡＭ点燃全然无效。提示ＡＥＳ的抗痫性有惊厥发作类型的选择性，副作用小。

关键词：抗痫灵戊五唑杏仁核点燃模型新药药理学

Deep diving in the PACIFIC:Practical issues in stage III non-small cell lung cancer to avoid shipwreck

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

World Journal of Clinical Oncology 2020年第11期11卷 898-917,I0003页

作者： Xabier Mielgo-Rubio Federico Rojo Laura Mezquita-Pérez Francesc Casas Amadeo wals.Manel Juan Carlos Aguado Javier Garde-Noguera David Vicente Felipe Couñago Department of Medical Oncology Hospital Universitario Fundación AlcorcónMadrid 28922Spain Department of Pathology IIS-Jiménez Díaz-CIBERONC FoundationMadrid 28040Spain Department of Medical Oncology Hospital ClinicLaboratory of Translational Genomics and Targeted Therapeutics in Solid TumorsIDIBAPSBarcelona 08036Spain Department of Radiation Oncology Hospital ClinicBarcelona 08036Spain Department of Radiation Oncology Hospital Universitario Virgen MacarenaSevilla 41009Spain Department of Immunology Service Hospital ClínicUniversitat de BarcelonaBarcelona 08036Spain Department of Medical Oncology Hospital Universitario Clínico San CarlosMadrid 28040Spain Department of Medical Oncology Hospital Universitario Virgen MacarenaSevilla 49001Spain Department of Radiation Oncology Hospital Universitario Quirónsalud MadridHospital La LuzUniversidad Europea de MadridMadrid 28028Spain

After publication of the PACIFIC trial results,immune check.oint inhibitor-based immunotherapy was included in the treatment algorithm of locally advanced non-small cell lung cancer(NSCLC).The PACIFIC trial demonstrated that 12 mo of durvalumab consolidation therapy after radical-intent platinum doublet chemotherapy with concomitant radiotherapy improved both progression-free survival and overall survival in patients with unresectable stage III *** is the first treatment in decades to successfully improve survival in this clinical setting,with manageable toxicity and without deterioration in quality of *** integration of durvalumab in the management of locally advanced NSCLC accentuates the need for multidisciplinary,coordinated decision-mak.ng among lung cancer specialists,bringing new challenges and controversies as well as important changes in clinical work.*** aim of the present article is to review—from a practical,multidisciplinary perspective—the findings and implications of the PACIFIC *** evaluate the immunobiological basis of durvalumab as well as practical aspects related to programmed cell death ligand 1 *** addition,we comprehensively assess the efficacy and toxicity data from the PACIFIC trial and discuss the controversies and practical aspects of incorporating durvalumab into routine clinical ***,we discuss unresolved questions and future *** short,the present document aims to provide clinicians with a practical guide for the application of the PACIFIC regimen in routine clinical practice.

关键词： Durvalumab Non-small cell lung cancer PACIFIC Immunotherapy Immune check.oint inhibitors Anti-programmed cell death ligand 1 Consolidation therapy Unresectable stage III lung cancer